Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

May 4, 2021 | Nightly News Rebroadcast | Video: 52 Minutes 29 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 4, 2021 | Video: 48 Minutes 40 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 4, 2021 | Video: 47 Minutes 37 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 4, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe

Show Me

As Global Pandemic Worsens, U.S. Keeps Blocking Vaccine Patent Waivers Amid Big Pharma Lobbying

Show Me

Kansas Legislature Overrides Governor’s Veto, Bans the Election Zuck Bucks. Plus: A Win for 2A Rights.

Show Me

(READ) Trump statement on “The Big Lie”

Show Me

Cheney slams Trump on ‘big lie’ over election

Show Me

Zuckerberg and George W. Bush Partner in Far Left Immigration Push.

Show Me

MS-13 Gang Member Nicknamed ‘Terror’ Gets Life In Jail for Killing Texas Teen

Show Me

Judicial Watch: Records Show Iowa State Officials Coordinated with Big Tech to Censor Election Posts

Show Me

Facebook oversight board to reveal decision on Trump ban on Wednesday

Show Me

Gray Television to be second largest broadcaster after $2.7B Meredith deal

Show Me

Modi Resists Pressure to Lock Down India as Virus Deaths Rise

Show Me

Sen. Scott ‘Hopeful’ on Police Reform as Democrats Now Looking for ‘Solution,’ Not ‘Issue’

Show Me

Verizon Agrees to Sell Yahoo, AOL to Apollo for $5 Billion

Show Me

May 3, 2021 | Nightly News Rebroadcast | Video: 52 Minutes 29 Seconds

Show Me

Trump Lawyer Jenna Ellis Challenges Liz Cheney to Debate on 2020 Election Integrity: ‘Name the Time and Place’

Show Me

Hillary Clinton voices concern on Biden’s Afghanistan withdrawal, warns of ‘unintended’ consequences

Show Me

New York area will lift capacity restrictions May 19

Show Me

Walgreens launching mobile clinics, walk-in COVID-19 vaccinations

Show Me

Austin residents vote to ban homeless encampments

Show Me

Denmark Ditches J&J COVID Vaccine, Says Benefits ‘Do Not Outweigh Risk’ of Blood Clots

Show Me

Florida Gov. DeSantis Suspends Local COVID-19 Emergency Orders, Bans Vaccine Passports

Show Me

The ‘Left’ Has Learned, The Quickest Way To Shut Down Your Opponent’s Objections Is To Call Them A ‘Racist’ | Just Ask ‘Minorities’ | “GOP Whip Montoya Blasts ‘race-baiting’ In Session”

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 3, 2021 | Video: 48 Minutes 24 Seconds

Show Me

Anti-Woke Faction Opposed To Critical Race Theory Wins Texas School Board Race

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 3, 2021 | Video: 48 Minutes 16 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 3, 2021 | Video: 40 Minutes 16 Seconds

Show Me

ADL’s Official Stance On Israel | “Support Israel: A Jewish and Democratic State”

Show Me

John Kerry Threatens Israel With Boycotts (2014)

Show Me

Former Security Adviser: John Kerry Undermined Trump in Unapproved Iran Talks

Show Me

ADL To Kerry: ‘Your Threats Destroy Peace Talks’ (2014)

Show Me

Apparently, Human Rights Watch Disagrees With ADL’s Stance On Israel | Video: 3 Minutes

Show Me

Gov. Abbott praised by Anti-Defamation League over racist posts by GOP leaders in Texas

Show Me

Texas GOP Chairman Allen West Joins Gab After Party Takes Account Down

Show Me

Could We Soon See Liz Cheney Gone from Leadership?

Show Me

Hubble Watches How a Giant Planet Grows

Show Me

Fake News: New York Times, WaPo, NBC forced to retract false claims about Giuliani

Show Me